Gainers
- Regulus Therapeutics RGLS stock increased by 12.4% to $1.45 during Thursday's after-market session. The company's market cap stands at $28.2 million.
- SeqLL SQL shares moved upwards by 10.34% to $15.79. The company's market cap stands at $6.0 million.
- bioAffinity Technologies BIAF shares moved upwards by 9.43% to $1.16. The market value of their outstanding shares is at $10.1 million.
- Enveric Biosciences ENVB shares increased by 9.05% to $2.65. The market value of their outstanding shares is at $5.7 million.
- Blue Water Biotech BWV shares rose 8.67% to $0.61. Trading volume for this security closed at 129.4K, accounting for 130.5% of its average full-day volume over the last 100 days. The company's market cap stands at $9.7 million.
- China Pharma Holding CPHI stock rose 7.01% to $0.14. At the close, China Pharma Holding's trading volume reached 65.8K shares. This is 7.2% of its average volume over the last 100 days. The company's market cap stands at $1.6 million.
Losers
- Baudax Bio BXRX shares decreased by 10.1% to $0.31 during Thursday's after-market session. The market value of their outstanding shares is at $2.8 million.
- Surrozen SRZN stock declined by 6.49% to $0.43. The market value of their outstanding shares is at $13.0 million.
- TransCode Therapeutics RNAZ stock decreased by 6.45% to $0.65. Today's trading volume for this security ended up closing at 583.3K shares, which is 103.7 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $1.3 million.
- IGC Pharma IGC stock fell 5.33% to $0.37. The market value of their outstanding shares is at $19.9 million.
- Taysha Gene Therapies TSHA stock declined by 4.63% to $2.89. The market value of their outstanding shares is at $540.3 million.
- TRACON Pharma TCON stock decreased by 4.57% to $0.21. The market value of their outstanding shares is at $6.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in